Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access
CDA and pCPA processes take considerable time and listing decisions by government drug plans add extra time before potential access by patients. Nearly all CDA reimbursement recommendations, which are intended for government drug plans (not private payers), are conditional.
Authors
- Nigel Rawson
Institutions
- Canadian Institute for Health Information (CA)
- Fraser Institute (CA)
- Arthur B. McDonald-Canadian Astroparticle Physics Research Institute (CA)
- Wilfrid Laurier University (CA)
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/ceor.s567932
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00